Skip to main content

Cozadd Bruce C's Form 4 filing

Jazz Pharmaceuticals plc (JAZZ) · filed Mar 4, 2026

Accession no.
0001193210-26-000005
Filed
Mar 4, 2026
Trade date
Mar 3, 2026
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions. Open-market sales total $1.12M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Cozadd Bruce CCIK 0001193210Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 3, 2026Ordinary SharesSSaleDisposed−3,159$186.09F2−$587,858.31408,637Direct
Mar 3, 2026Ordinary SharesSSaleDisposed−2,608$186.73F3−$486,991.84406,029Direct
Mar 3, 2026Ordinary SharesSSaleDisposed−233$187.84F4−$43,766.72405,796Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $185.500 to $186.4207. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Referenced by the price of 1 transaction in Table I.

F3

Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $186.500 to $187.4693. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Referenced by the price of 1 transaction in Table I.

F4

Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $187.7783 to $188.1678 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)